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Abstract 12 
Dengue virus (DENV), Yellow Fever virus, West Nile virus, Japanese encephalitis virus and Zika 13 
virus are medically important flaviviruses transmitted to humans by mosquitoes and circulate in 14 
overlapping geographic areas. Cross-reactive immune responses have been demonstrated among 15 
the flaviviruses, particularly the four DENV serotypes. The immunological imprint left by a 16 
flavivirus infection can therefore have profound effects on the responses to subsequent infections. 17 
In this review we summarize recent research focusing on T cell responses to DENV using clinical 18 
samples from prospective cohort studies in Asia. These data suggest that durability of different T 19 
cell populations after natural infection or vaccination is an important consideration for the outcome 20 
of subsequent flavivirus exposures and we argue for continued investigation in the context of 21 
longitudinal cohort studies.  22 
Introduction 23 
The flavivirus genus in the Flaviviridae family of positive-strand RNA viruses includes over 33 24 
viruses known to infect humans [1]. Among these, the four dengue virus (DENV) serotypes, 25 
DENV1-4, represent a major global health problem, infecting an estimated 400 million individuals 26 
each year [2]. A world-wide pandemic of Zika virus (ZIKV) infections occurred from 2015-2016, 27 
and there remains the potential for future large outbreaks. Since these five viruses are transmitted 28 
by the same mosquito vectors, Aedes aegypti and Aedes albopictus, the population living in 29 
affected areas remain at risk for repeated exposures over their lifetime. Additionally, the 30 
geographic distribution of DENV overlaps substantially with that of other flaviviruses, such as 31 
yellow fever virus (YFV, which shares the same mosquito vector), West Nile virus (WNV), and 32 
Japanese encephalitis virus (JEV). 33 
The flaviviruses vary in the degree of genetic relatedness, with the four DENV serotypes forming 34 
a distinct cluster in the phylogenetic tree. ZIKV is next most closely related to the DENV group, 35 
with YFV, WNV, and JEV having greater genetic divergence. The genetic relatedness among these 36 
viruses, discovered through the application of high-throughput sequencing, explains the serologic 37 
cross-reactivity among these viruses that was reported over 50 years earlier by Casals and others 38 
[3]. Serologic studies also established the concept that one flavivirus infection significantly 39 
modified the immune response to any subsequent flavivirus infection, resulting in high-titer cross-40 
reactive antibody responses. These observations then led to the insight that severe dengue illness 41 
was strongly associated with secondary DENV infections [4]. 42 
We and other cellular immunologists recognized the potential parallels between these serologic 43 
observations and T lymphocyte responses to flaviviruses, and, further, the diversity of functional 44 
responses possible as a result of activation of cross-reactive memory T cells during a second 45 
flavivirus infection [5–7]. Initial characterizations of flavivirus-reactive T cells confirmed 46 
antigenic cross-reactivity as well as altered responses after secondary flavivirus infection. As has 47 
been the case for antibodies, these studies provided only circumstantial evidence of a potential 48 
important contribution of cellular immunity to flavivirus infection outcomes. Our recent studies 49 
have sought to establish the clinical relevance of these responses to better understand individual 50 
risk factors for severe dengue illness and correlates of vaccine efficacy and safety. 51 
Technical considerations in studies of flavivirus-specific T cell immunity 52 
A major focus of our attention in recent years has been on study design and its consequences for 53 
the interpretation of results. Experimental flavivirus infection models have offered the greatest 54 
level of control over important parameters, e.g., the timing of viral challenge and sampling, size 55 
of challenge inoculum, and genetic background of the host. These models have enabled studies 56 
demonstrating, e.g., the impact of specific infection sequences and interactions with host genetics 57 
on both acute and memory phases of the T cell response [8]. However, the failure of most 58 
laboratory mice to faithfully recapitulate human infection and disease has been problematic for 59 
translation of these findings to humans. While a number of innovative models have been developed 60 
to address this limitation, such as “humanized” mouse strains and experimental infection of 61 
humans with modified viruses, studies of natural flavivirus infection remain an essential element 62 
of the research agenda [9]. 63 
Table 1 summarizes several key considerations in the design of observational studies of cellular 64 
immunity to flavivirus infections, and their implications for interpretation of study results. Several 65 
factors address the selection of subjects and specimens for analysis. Many studies have used blood 66 
samples collected either during or after an acute flavivirus infection, due to the ready availability 67 
of suitable patient populations in flavivirus-endemic areas [6,10–14]. This study design simplifies 68 
the collection of specimens for detailed immunological characterization, and, with high-quality 69 
associated clinical data, identifies associations with illness and generates hypotheses regarding 70 
causality. However, it is clear that key immunological events precede even studies of the early 71 
phase of illness; a prospective cohort study design is therefore essential to explore the role of 72 
immune responses as predictors of risk. Clinical data available for statistical analyses is dependent 73 
on the sample collection strategy, and also introduces additional complexity. A common 74 
comparison, subjects with mild versus severe illness, relies on clear and consistently-applied 75 
clinical definitions. Mistakes in applying the criteria for dengue fever (DF) and dengue 76 
hemorrhagic fever (DHF) have been cited as an issue, but the newer classifications of dengue with 77 
warning signs (DWS) and severe dengue (SD) have in many ways been more problematic, as 78 
illustrated by the finding that antibody titers were more strongly associated with the earlier 79 
classification [15]. We have preferred the DF/DHF classification for symptomatic infections, 80 
which more clearly emphasizes plasma leakage as the principal component of more severe illness. 81 
We have also used continuous measures of plasma leakage, thrombocytopenia, and liver injury; 82 
this has allowed us to identify immunological associations with particular disease indicators [16]. 83 
The functional responses measured and their cross-reactivity for different flaviviruses are 84 
determined by the assay format and selection of antigens. A thorough treatment of these technical 85 
issues is beyond the scope of the current review, but several examples of relevant considerations 86 
are listed in Table 1. In particular, our strategy has been to measure the responses to individual 87 
viruses, e.g., DENV1-4, rather than to develop a single measure, as in the megapool strategy, 88 
because the distribution of different clinical outcomes is critically dependent on the specific virus 89 
with which each individual is infected. 90 
 91 
Table 1. Considerations in the design of observational studies of cellular immunity in flavivirus 92 
infections. 93 
Factor Options Implications 
Timing of sample collection Pre-infection 
During acute infection 
Post-infection 
Pre-infection responses have 
predictive potential; acute 
responses reflect pathophysiology 
+/- pathogenesis 
Clinical phenotypes Severe illness 
Mild illness 
Inapparent infection 
Exposed without infection 
Severe versus mild illness reflects 
pathophysiology, but both involve 
productive infection; inapparent 
dependent on surveillance, 
difficult to define exposure 
T cell functions Activation 
Cytokine production- IFN, 
TNF, others 
Cytolysis 
Effector functions that are most 
protective not well defined; many 
T cell functions also have 
potential role in disease 
pathogenesis 
Antigen stimulation No stimulation v stimulation 
Peptides v virus/infected cell 
Whole proteome v selected 
Single v multiple viruses 
Measures the presence or function 
of T cells; affects percentage of 
virus-specific T cell repertoire 
detected (based on antigen 
specificity and/or T cell subset) 
 94 
Cross-reactivity and functional diversity of flavivirus-reactive T cells 95 
T cells are highly heterogeneous in peptide sequence specificity and functional responses. These 96 
are particularly important considerations for flavivirus-specific T cells given the potential 97 
implications for secondary flavivirus infections. Recipients of monovalent live flavivirus vaccines 98 
have been useful to characterize these responses due to their ability to donate large volumes of 99 
blood and well-defined virus exposure, often without confounding exposures to other flaviviruses 100 
[17,18]. Multiparameter flow cytometry of antigen-stimulated memory T cells has shown 101 
heterogeneous cytokine production at the single cell level for both CD4 [19] and CD8 [20] T cells. 102 
Although overall the highest frequencies of cytokine-producing T cells were observed in response 103 
to the homologous DENV serotype, in the case of some epitopes higher responses were observed 104 
to heterologous peptides. Additionally, the relative frequencies of T cells producing IFN versus 105 
TNF or MIP-1 varied for different epitope variants. These data have demonstrated the potential 106 
for flavivirus antigens to act as altered peptide ligands for memory T cells during infection in 107 
individuals who have had a prior heterologous flavivirus exposure. 108 
Although vaccines offer advantages as model live flavivirus infections, associations with 109 
infrequent clinical phenotypes and with sequential infection have continued to require the study of 110 
natural infections with wild-type viruses. In addition to a careful and thorough characterization of 111 
study subjects, we have found it important to analyze sequential blood samples starting before the 112 
critical phase of illness. Using flow cytometry, we have demonstrated that multiple populations of 113 
CD4 and CD8 T cells are activated and expanded during acute infection, and that this expansion 114 
precedes the development of plasma leakage [6,12]. In one recent study [12], we found a higher 115 
number of activated pTFH cells during the critical phase of illness in subjects with secondary 116 
infections and those with DHF; the frequency of activated pTFH cells also correlated with antibody 117 
responses. While most studies from our group and others have pointed to a positive association 118 
between immune activation and disease severity, the direction of causality has remained a point of 119 
controversy. 120 
Associations of pre-existing flavivirus-reactive T cell responses with clinical phenotype 121 
Our efforts to address this causal relationship has directed our efforts towards the analysis of blood 122 
samples collected through prospective cohort studies. These studies have encountered several 123 
challenges, such as the low frequency of severe clinical phenotypes, limited blood samples from 124 
young subjects, and the large number of immune responses of interest based on the studies of acute 125 
infection. We have therefore applied several different laboratory methods (Table 2).  126 
In our first study [19], we selected subjects with symptomatic secondary DENV infections. PBMC 127 
were stimulated with inactivated DENV antigens and we compared proliferation and cytokine 128 
secretion in subjects with hospitalized (more severe) versus non-hospitalized (less severe) dengue. 129 
There was no significant difference in T cell proliferation, however, IFN-γ production to multiple 130 
serotypes was associated with milder illness and TNFα production was associated with more 131 
severe illness. In our second study [21], we used the same stimulation method but measured the 132 
frequency of cytokine-producing CD4 T cells by flow cytometry. We compared responses in 133 
subjects with subclinical infection to those in subjects with symptomatic infection (regardless of 134 
severity of illness). This study found that subjects with subclinical infection had higher frequencies 135 
of CD4 T cells producing IFN- or IL-2 in response to DENV antigen than subjects with 136 
symptomatic infection. To extend these findings, we selected another subset of subjects with 137 
subclinical and symptomatic infections, and measured both the frequencies of responding cells as 138 
well as cytokine secretion in response to stimulation in vitro [22]. This study confirmed the 139 
association of higher frequencies of IFN--producing CD4 T cells with subclinical infection. We 140 
found that the secretion of IL-6, IL-15 and MCP-1 was higher by PBMC from children who 141 
developed symptomatic DENV infection, whereas the secretion of IL-12, IL-2R, MIP-1-α, 142 
RANTES, GM-CSF, and TNF-α was lower by PBMC from these children. These studies paint a 143 
complex picture of opposing positive/protective and negative/pathological effects of pre-existing 144 
flavivirus-specific T cell responses on the outcome of secondary DENV infection. 145 
 146 
Table 2. Comparison of studies to identify clinical associations of dengue virus-specific immune 147 




In vitro stimulation Measurements 







infected cell lysate (7 d) 
Proliferation 
IFN-, TNF secretion 





infected cell lysate (24 h) 
% cytokine-positive CD4 T 
cells (IFN-, TNF, IL-2) 






infected cell lysate (24 h) 
% IFN--positive CD4 T 
cells 
Infectious DENV (7 d) Cytokine secretion 
 149 
Temporal changes in responses of flavivirus-reactive T cells 150 
Most studies of flavivirus-specific memory T cells, including those described above, have based 151 
their conclusions on a single time point. However, the stability of T cell memory has not been well 152 
characterized, particularly in settings where frequent re-exposures are possible. We have recently 153 
leveraged the longitudinal nature of our cohort study to address this gap. We measured DENV-154 
specific T cell responses by IFN/IL-2 ELISPOT assays in PBMC collected over 5 consecutive 155 
years from individuals who had a symptomatic, subclinical or no DENV infection [23]; subclinical 156 
and no infection groups were defined serologically. DENV-specific T cells were low or absent 157 
before symptomatic secondary infection. Increased responses were observed following the 158 
infection, however, they fluctuated over the 3-4 years after infection. We observed some increases 159 
in T cell responses in the absence of serologic evidence of infection, raising the possibility of 160 
inapparent viral exposures. Furthermore, some subjects, particularly those who did not experience 161 
a symptomatic DENV infection during the study, showed greater stability in immune responses. 162 
The above findings have led us to hypothesize that the durability of flavivirus-specific T cell 163 
responses after an infection and the cytokine responses of T cells that persist at low frequency may 164 
represent critical determinants of the outcome of a subsequent infection. Recently we have been 165 
studying the kinetics of T cell responses over multiple years prior to infection in subjects with mild 166 
(non-hospitalized) or severe (DHF) illness from our prospective cohort study [23]. To increase the 167 
sensitivity for low-frequency responses, we are using cultured ELISPOT assays [24]. Figure 1 168 
shows two examples of responses over time to a structural protein peptide pool (less serotype-169 
crossreactive) and a non-structural protein peptide pool (more serotype-crossreactive) in 170 
individuals who had a symptomatic DENV-2 infection in 2001. IFN T cell responses were low in 171 
2001; in one subject, this followed a decline over several years in responses to non-structural 172 
proteins. Post-infection, responses were significantly increased to both structural and non-173 
structural proteins. 174 
Implications for flavivirus vaccines 175 
Applying the lessons from natural flavivirus infections to improve the design of vaccine products 176 
and dosing regimens remains a key goal for us and many others. There are currently a significant 177 
number of flavivirus vaccines in clinical testing [25,26]. We and others have characterized the 178 
flavivirus-specific T cell responses induced by different formulations and regimens of these 179 
vaccines [27,28]. Friberg et al demonstrated the complementary information that can be obtained 180 
from applying a suite of immune responses assays, including ELISPOT, cytokine flow cytometry, 181 
proliferation, and cytokine secretion assays [29]. Detailed single-cell analyses have demonstrated 182 
the power to identify distinct gene expression and metabolic features of T cell destined to persist 183 
into the memory phase [30]. However, the cohort studies described above suggest a cautious 184 
approach to translating those findings to children in flavivirus-endemic areas, where blood samples 185 
volumes are more limited and both pre-existing immunity and frequent re-exposures are likely. 186 
We are applying the lessons we have learned from cohort studies of natural infection to a cohort 187 
of Filipino children who received DengvaxiaTM as part of the phase III efficacy trial. Figure 1 188 
shows examples of apparent vaccine responses. Pre-vaccination PBMC in these cases showed low 189 
flavivirus-specific T cell responses, as was observed in our Thai cohort study; post-vaccination 190 
PBMC showed responses to some DENV structural proteins and YFV NS3 protein, but not to 191 
DENV non-structural proteins. Follow-up of this cohort will determine whether vaccine-induced 192 
immune responses are associated with protection against subsequent DENV infection. 193 
Remaining questions 194 
Recent studies have greatly advanced the characterization of flavivirus-specific T cell responses 195 
during both acute and memory phases. As illustrated in Figure 2, many functionally distinct T cell 196 
subpopulations are now known to be recruited into the acute response to natural infection and 197 
persist into memory, where they are capable of influencing the outcome of subsequent infections. 198 
Host genetic factors influence both the magnitude and specificity of this response. Qualitatively 199 
and quantitatively similar responses have also been observed in the acute and early memory phases 200 
after immunization of some, but not all vaccine candidates. 201 
At the same time that technological advances have enhanced the detail in our understanding of 202 
components of T cell responses to flavivirus infection and vaccination, we risk losing perspective 203 
on the clinical relevance of these findings, like the proverbial blind men describing the elephant. 204 
Data suggest that the balance between different immune responses over the entire course of 205 
infection affects the clinical outcome (Figure 2 bottom). Persistence of memory responses, and the 206 
impact of sequential exposures to circulating viruses and vaccines, are important influences on the 207 
immunological repertoire at the time of exposure. What factors determine the durability of 208 
flavivirus-specific memory after natural infection and vaccination? Which components of memory 209 
contribute most to the clinical outcome of subsequent infection? How does the lifetime history of 210 
flavivirus exposures affect these associations? Given the co-circulation of multiple flaviviruses, 211 
host and viral genetic differences, and variable time intervals, the number of permutations to be 212 
considered is enormous. We believe that studies of carefully selected cohorts of subjects with 213 
detailed clinical characterization offer critical insights into these questions and should remain a 214 
high priority for further study. 215 
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Figure legends 332 
Figure 1. Illustrative examples of DENV-specific T cell responses in cohort studies. A. 333 
Longitudinal analysis of DENV-specific T cells in a prospective cohort of Thai children. 334 
Frequencies of IFN-γ spot-forming cells (SFC) detected in cultured ELISPOT assays after 335 
restimulation with peptide pools from DENV-2 structural (2prM/E) or non-structural (2NSA) 336 
proteins using PBMC collected at the indicated time points; subjects experienced a secondary 337 
DENV-2 infection in 2001. NT, not tested. B. Analysis of DENV-specific T cell responses to 338 
vaccination in a Philippine cohort. Frequencies of IFN- SFC detected in ex vivo ELISPOT assays 339 
after stimulation with peptide pools from structural (prM/E) or non-structural (NSA) proteins of 340 
each DENV serotype or NS3 protein of YFV using PBMC collected prior to vaccination (V01), 1 341 
month after the first vaccination (V02), or 1 month after the third vaccination. 342 
Figure 2. Model of T cell involvement in dengue disease. A) Different subsets of T cells are 343 
induced during DENV infections. In a primary DENV infection, serotype-specific T cells are 344 
activated including cytotoxic T cells, helper T cells comprising the recent described TFH cells & 345 
Tregs. In the course of convalescent-phase, TEM & TCM are the long-term memory subsets. These 346 
memory T cell pools are modified by a second flavivirus infection or vaccination resulting in the 347 
expansion of cross-reactive and recently activated serotype-specific clones. B) Multiple factors 348 
associated with disease severity. Factors listed on the left side are hypothesized to contribute to 349 
enhanced disease severity; factors listed on the right are hypothesized to contribute to protection 350 
from infection and/or illness.  351 
